This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Carvedilol

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

7

Spl Product Data Elements

Carvedilol Carvedilol CARVEDILOL CARVEDILOL CROSPOVIDONE (12 MPA.S AT 5%) HYPROMELLOSE, UNSPECIFIED LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE K30 SILICON DIOXIDE TALC TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND Z;1 Carvedilol Carvedilol CARVEDILOL CARVEDILOL CROSPOVIDONE (12 MPA.S AT 5%) HYPROMELLOSE, UNSPECIFIED LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE K30 SILICON DIOXIDE TALC TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND ZC40 Carvedilol Carvedilol CARVEDILOL CARVEDILOL CROSPOVIDONE (12 MPA.S AT 5%) HYPROMELLOSE, UNSPECIFIED LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE K30 TALC TITANIUM DIOXIDE SILICON DIOXIDE WHITE TO OFF-WHITE ROUND ZC41 Carvedilol Carvedilol CARVEDILOL CARVEDILOL CROSPOVIDONE (12 MPA.S AT 5%) HYPROMELLOSE, UNSPECIFIED LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE K30 TALC TITANIUM DIOXIDE SILICON DIOXIDE WHITE TO OFF-WHITE ROUND ZC42

Application Number

ANDA077614

Brand Name

Carvedilol

Generic Name

Carvedilol

Product Ndc

65841-618

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-616-01 in bottle of 100 Tablets Carvedilol Tablets USP, 3.125 mg R x only 100 Tablets NDC 65841-617-01 in bottle of 100 Tablets Carvedilol Tablets USP, 6.25 mg R x only 100 Tablets NDC 65841-618-01 in bottle of 100 Tablets Carvedilol Tablets USP, 12.5 mg R x only 100 Tablets NDC 65841-619-01 in bottle of 100 Tablets Carvedilol Tablets USP, 25 mg R x only 100 Tablets Carvedilol Tablets, 3.125 mg Carvedilol Tablets, 6.25 mg Carvedilol Tablets, 12.5 mg Carvedilol Tablets,25 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.